Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors

被引：54
作者：
Abdou, Yara [1 ]
Goudarzi, Atta [2 ]
Yu, Jia Xin [3 ]
Upadhaya, Samik [4 ]
Vincent, Benjamin [1 ]
Carey, Lisa A. [1 ]
机构：
[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[2] Univ Buffalo, Dept Med, Buffalo, NY 14203 USA
[3] Parker Inst Canc Immunotherapy, San Francisco, CA 94129 USA
[4] Canc Res Inst, New York, NY 10006 USA
来源：
NPJ BREAST CANCER | 2022年 / 8卷 / 01期
关键词：
TUMOR-INFILTRATING LYMPHOCYTES; RANDOMIZED PHASE-II; METASTATIC BREAST; NEOADJUVANT CHEMOTHERAPY; TALIMOGENE LAHERPAREPVEC; T-CELLS; PEPTIDE VACCINE; DENDRITIC CELLS; DOUBLE-BLIND; TRIAL;
D O I：
10.1038/s41523-022-00486-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The development of immunotherapy agents has revolutionized the field of oncology. The only FDA-approved immunotherapeutic approach in breast cancer consists of immune checkpoint inhibitors, yet several novel immune-modulatory strategies are being actively studied and appear promising. Innovative immunotherapeutic strategies are urgently needed in triple negative breast cancer (NBC), a subtype of breast cancer known for its poor prognosis and its resistance to conventional treatments. TNBC is more primed to respond to immunotherapy given the presence of more tumor infiltrating lymphocytes, higher PD-L1 expression, and higher tumor mutation burden relative to the other breast cancer subtypes, and therefore, immuno-oncology represents a key area of promise for TNBC research. The aim of this review is to highlight current data and ongoing efforts to establish the safety and efficacy of immunotherapeutic approaches beyond checkpoint inhibitors in TNBC.
引用
收藏
页数：10
相关论文
共 116 条
  • [31] PROGNOSTIC VALUE OF CEA AND FERRITIN ASSAY IN BREAST-CANCER - A MULTIVARIATE-ANALYSIS
    GAGLIA, P
    CALDAROLA, B
    BUSSONE, R
    POTENTE, F
    LAURO, D
    JAYME, A
    CALDAROLA, L
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (07): : 1151 - 1155
  • [32] Driving T-cell immunotherapy to solid tumors
    Garber, Ken
    [J]. NATURE BIOTECHNOLOGY, 2018, 36 (03) : 215 - 219
  • [33] Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting
    Garcia-Teijido, Paula
    Luque Cabal, Maria
    Pelaez Fernandez, Ignacio
    Fernandez Perez, Yolanda
    [J]. CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2016, 10 : 31 - 39
  • [34] If we build it they will come: targeting the immune response to breast cancer
    Gatti-Mays, Margaret E.
    Balko, Justin M.
    Gameiro, Sofia R.
    Bear, Harry D.
    Prabhakaran, Sangeetha
    Fukui, Jami
    Disis, Mary L.
    Nanda, Rita
    Gulley, James L.
    Kalinsky, Kevin
    Sater, Houssein Abdul
    Sparane, Joseph A.
    Cescon, David
    Page, David B.
    McArthur, Heather
    Adams, Sylvia
    Mittendorf, Elizabeth A.
    [J]. NPJ BREAST CANCER, 2019, 5 (1)
  • [35] Immunization of metastatic breast cancer patients with a fully synthetic globe H conjugate: A phase I trial
    Gilewski, T
    Ragupathi, G
    Bhuta, S
    Williams, LJ
    Musselli, C
    Zhang, XF
    Bencsath, KP
    Panageas, KS
    Chin, J
    Hudis, CA
    Norton, L
    Houghton, AN
    Livingston, PO
    Danishefsky, SJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (06) : 3270 - 3275
  • [36] Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
    Gulley, James L.
    Arlen, Philip M.
    Tsang, Kwong-Yok
    Yokokawa, Junko
    Palena, Claudia
    Poole, Diane J.
    Remondo, Cinzia
    Cereda, Vittore
    Jones, Jacquin L.
    Pazdur, Mary P.
    Higgins, Jack P.
    Hodge, James W.
    Steinberg, Seth M.
    Kotz, Herbert
    Dahut, William L.
    Schlom, Jeffrey
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (10) : 3060 - 3069
  • [37] Preliminary safety data of intrahepatic talimogene laherparepvec and intravenous atezolizumab in patients with triple negative breast cancer
    Hecht, Joel Randolph
    Chan, Arlene
    Baurain, Jean-Francois
    Martin, Miguel
    Longo-Munoz, Federico
    Kalinsky, Kevin
    Raman, Steven
    Liu, Chunxu
    Cha, Edward
    Chan, Emily
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [38] Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer A Randomized Clinical Trial
    Heery, Christopher R.
    Ibrahim, Nuhad K.
    Arlen, Philip M.
    Mohebtash, Mahsa
    Murray, James L.
    Koenig, Kimberly
    Madan, Ravi A.
    McMahon, Sheri
    Marte, Jennifer L.
    Steinberg, Seth M.
    Donahue, Renee N.
    Grenga, Italia
    Jochems, Caroline
    Farsaci, Benedetto
    Folio, Les R.
    Schlom, Jeffrey
    Gulley, James L.
    [J]. JAMA ONCOLOGY, 2015, 1 (08) : 1087 - 1095
  • [39] Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury
    Heery, Christopher R.
    Singh, B. Harpreet
    Rauckhorst, Myrna
    Marte, Jennifer L.
    Donahue, Renee N.
    Grenga, Italia
    Rodell, Timothy C.
    Dahut, William
    Arlen, Philip M.
    Madan, Ravi A.
    Schlom, Jeffrey
    Gulley, James L.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2015, 3 (11) : 1248 - 1256
  • [40] A randomized phase II study of nab-paclitaxel plus durvalumab plus neoantigen vaccine versus nab-paclitaxel plus durvalumab in metastatic triple-negative breast cancer (mTNBC).
    Hernandez-Aya, Leonel Fernando
    Gao, Feng
    Goedegebuure, Peter S.
    Ma, Cynthia X.
    Ademuyiwa, Foluso Olabisi
    Park, Haeseong
    Peterson, Lindsay Leuthen
    Bagegni, Nusayba Ali
    Bose, Ron
    Gillanders, William E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345678910